Delayed-Onset High Altitude Pulmonary Edema: A Case Report.
acetazolamide
acute mountain sickness
altitude illness
Journal
Wilderness & environmental medicine
ISSN: 1545-1534
Titre abrégé: Wilderness Environ Med
Pays: United States
ID NLM: 9505185
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
01
04
2018
revised:
07
11
2018
accepted:
12
11
2018
pubmed:
16
1
2019
medline:
21
3
2019
entrez:
16
1
2019
Statut:
ppublish
Résumé
High altitude pulmonary edema (HAPE) is a life-threatening altitude illness that usually occurs in insufficiently acclimatized climbers in the first few days at altitudes above 2500 m. Acetazolamide is recommended for prophylaxis of acute mountain sickness, but a role for acetazolamide in the prevention of HAPE has not been established. We report a case of a trekker with previous high altitude experience who developed HAPE 8 d after arrival to altitude despite what was believed to be a conservative ascent profile.
Identifiants
pubmed: 30642713
pii: S1080-6032(18)30208-4
doi: 10.1016/j.wem.2018.11.002
pii:
doi:
Substances chimiques
Nifedipine
I9ZF7L6G2L
Oxygen
S88TT14065
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-92Informations de copyright
Copyright © 2018 Wilderness Medical Society. Published by Elsevier Inc. All rights reserved.